The Claim
In patients with acute coronary syndrome on statin therapy, high-dose eicosapentaenoic acid (EPA) is associated with a greater reduction in low-density lipoprotein cholesterol (LDL-C) compared to low-dose omega-3 combinations, but this difference in LDL-C reduction does not fully account for the observed reduction in plaque progression.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people with heart disease who are already taking statins, taking a high dose of EPA (a type of fish oil) seems to lower 'bad' cholesterol more than lower doses of other omega-3s—but even with that extra cholesterol drop, something else about EPA is still helping reduce artery plaque.
See the scientific wording
In patients with acute coronary syndrome on statin therapy, high-dose eicosapentaenoic acid (EPA) is associated with a greater reduction in low-density lipoprotein cholesterol (LDL-C) compared to low-dose omega-3 combinations, but this difference does not fully explain the observed reduction in plaque progression.
What the research says
1 studyTaking a high dose of EPA (a type of fish oil) along with statins helped reduce dangerous buildup in heart arteries more than taking little or no EPA, even though the statins were already being used. This suggests EPA helps in ways that aren't just about lowering bad cholesterol.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.